RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
Rocket Pharmaceuticals drops despite the FDAs accelerated approval of gene therapy Kresladi in severe leukocyte adhesion deficiency-I, an ultra-rare disease.…
3,445$
-8,62%
Echtzeit-Aktienkurs Rocket Pharmaceuticals Corp.
Bid:
Ask:
Nachrichten zur Rocket Pharmaceuticals Corp. Aktie
Rocket Pharmaceuticals: Kresladi Approval Validates Platform, But Commercial Upside Remains Limited
…
Rocket Pharmaceuticals secures FDA approval for gene therapy KRESLADI
Rocket Pharmaceuticals (NASDAQ:RCKT) announced that the US Food and Drug Administration (FDA) has granted accelerated approval for KRESLADI (marnetegragene...…
Wedbush sees Rocket Pharmaceuticals as significantly undervalued as cardiac gene therapy pipeline advances
The broker maintains its outperform rating and $16 price target on shares trading at $4.97 Wedbush Securities has reiterated its…
RCKTs Q4 Loss Narrower Than Estimated, Pipeline in Focus
Rocket Pharmaceuticals reports narrower-than-estimated Q4 loss. The company provides key updates on its pipeline candidates. Stock rises in after-hours trading.…
Rocket Pharmaceuticals: Deep Dislocation Offers Asymmetric Upside On LAD-I Approval And Amended Danon Program
…
Shareholders that lost money on Rocket Pharmaceuticals, Inc.(RCKT) Urged to Join Class Action – Contact The Gross Law Firm to Learn More
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…
RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law
SAN DIEGO, July 26, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP…
FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action– Hagens Berman
SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed…
Rocket Pharmaceuticals names Christopher Stevens as chief operating officer By Investing.com
Rocket Pharmaceuticals names Christopher Stevens as chief operating officer…
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman
SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals,…
RCKTs IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance
FDA clears Rocket Pharmaceuticals IND for RP-A701, advancing its gene therapy for BAG3-linked dilated cardiomyopathy.…
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman
SAN FRANCISCO, June 30, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals,…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of …
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of …
RCKT Stock Tanks on Patient Death in Danon Disease Study
Rocket Pharmaceuticals plunges after a patient death in its Danon disease study, prompting a voluntary dosing pause. The FDA puts…
Rocket Pharmaceuticals shares plunge after FDA halts key gene therapy trial following patient death
Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) sank nearly 60% on Tuesday morning after the company disclosed that the US Food and…
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.…
Rocket Pharmaceuticals: Not Bad Valuation But Reflexivity Risks Remain
…
Rocket Pharmaceuticals Q3 Earnings Beat, Pipeline in Focus
RCKT incurs narrower-than-expected third-quarter 2024 loss. The company provides updates on its pipeline candidates.…
Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review
…
Global Regenerative Medicine Market Size To Worth USD 349.93 Billion By 2033 | CAGR of 27.06%
The Global Regenerative Medicine Market Size was Valued at USD 31.90 Billion in 2023 and the Worldwide Regenerative Medicine Market…
Rocket Pharmaceuticals: CRL For Kresladi Unwelcome, But Likely A Quick Fix
…
Rockets (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
Rocket Pharmaceuticals (RCKT) first-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the…
Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)
…
Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch
…
Rocket Pharmaceuticals appoints Aaron Ondrey as CFO
…
Rocket Pharmaceuticals director sells over $7.79 million in company stock By Investing.com
Rocket Pharmaceuticals director sells over $7.79 million in company stock…
Rocket Pharmaceuticals executive sells over $69k in company stock By Investing.com
Rocket Pharmaceuticals executive sells over $69k in company stock…
Rocket Pharmaceuticals Promising Path In Gene Therapy
…
Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4
Rocket Pharmaceuticals (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the…